Retension Pharmaceuticals, Inc. (RTSN)
10.69
-0.03
(-0.28%)
USD |
NASDAQ |
Nov 06, 10:17
Retension Pharmaceuticals Net Income (Quarterly) : -4.171M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.171M |
| March 31, 2026 | -3.354M |
| Date | Value |
|---|---|
| June 30, 2025 | -1.229M |
| March 31, 2025 | -0.6565M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AbbVie, Inc. | 4.207B |
| Abeona Therapeutics, Inc. | -20.19M |
| America Great Health | -0.1662M |
| Acumen Pharmaceuticals, Inc. | -25.37M |
| Aardvark Therapeutics, Inc. | -14.39M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 4.171M |
| EPS Diluted (Quarterly) | -0.5292 |
| Enterprise Value | 99.17M |
| Earnings Yield | -11.17% |
| Normalized Earnings Yield | -11.17 |